Since 1998 he has been Director of the Epilepsy Unit at the Ruber International Hospital in Madrid, a pioneering centre for the diagnosis, medical and surgical treatment of epilepsy in children and adults.
More than 150 neurologists and neurophysiologists from Spain and Latin America have been trained here, and several of its students have successfully opened epilepsy centres in other public and private hospitals, both in Spain and abroad.
The program he directs has become a pioneer in Spain in the field of genetic diagnosis of complex epilepsies and advanced treatments such as drug repositioning, interstitial laser treatment, deep electrodes and gamma radiosurgery, which are used in patients with refractory epilepsy.
Dr. Antonio Gil-Nagel is a professor at the IE University, is an Ad Honorem Professor at the Center for Biomedical Technology of the Polytechnic University of Madrid (CTB) and is Director of the Epilepsy Department at the Francisco Vitoria University of Madrid.
He was a founding member of the European Epilepsy Research Network and the European Association for Epilepsy Monitoring. He is also active in international research projects such as EpiCare and the European Epilepsy Brain Bank and has held relevant positions in international institutions such as the International Bureau for Epilepsy (IBE), the International League Against Epilepsy (ILAE), the European Federation of Neurological Societies (EFNS) and the World Federation of Neurology (WFN).
Dr. Gil-Nagel has directed numerous clinical trials and research studies in the field of epilepsy, especially in orphan epilepsies such as Dravet syndrome, Lennox-Gastaut syndrome and other epileptic and developmental encephalopathies. The Epilepsy Program he directs is an international benchmark in the development of pharmacological research. He has been the Principal Investigator of phase II and III clinical trials, including numerous clinical trials and non-pharmacological treatments (epilepsy surgery, electrical stimulation, ketogenic diet and gamma knife). His research is funded by European Union funds and the Public Innovation Agency of the Ministry of Science and Innovation of the Spanish Government. Their dedication to research and the development of new treatments allows them to accelerate the treatment of their patients with new treatments.
In addition to being a frequent speaker at national and international conferences, he has authored several books on epilepsy and electroencephalography and has numerous publications on epilepsy in journals such as Annals of Neurology, Brain, Epilepsy, European Journal of Neurology, Journal of Neurology, Nature Neurology, Neurology, and the New England Journal of Medicine, among others. He has authored 165 Scopus-indexed articles with 5,265 citations and an h-index of 35.
In 2021, his team received the Innovative Small and Medium Enterprise Award for the project on mesial temporal lobe epilepsy and encephalocele (Ministry of Science and Innovation, Spain), and in 2012, the Scientific Award from the Epilepsy Group of the Spanish Society of Neurology (SEN).
Dr. Hill-Nagel is a leading international figure in the field of epileptology, a recognized expert in the diagnosis and treatment of genetic epilepsy and the surgical approach to its correction. His distinguished professional career includes many years of experience in leading medical institutions in the United States and Europe, as well as active participation in international research and educational programs.
Dr. Hill-Nagel not only advances the science of neurology on a global level, but also successfully implements cutting-edge treatment methods, improving the lives of thousands of patients around the world.
اقرأ المزيدSince 1998 he has been Director of the Epilepsy Unit at the Ruber International Hospital in Madrid, a pioneering centre for the diagnosis, medical and surgical treatment of epilepsy in children and adults.
More than 150 neurologists and neurophysiologists from Spain and Latin America have been trained here, and several of its students have successfully opened epilepsy centres in other public and private hospitals, both in Spain and abroad.
The program he directs has become a pioneer in Spain in the field of genetic diagnosis of complex epilepsies and advanced treatments such as drug repositioning, interstitial laser treatment, deep electrodes and gamma radiosurgery, which are used in patients with refractory epilepsy.
Dr. Antonio Gil-Nagel is a professor at the IE University, is an Ad Honorem Professor at the Center for Biomedical Technology of the Polytechnic University of Madrid (CTB) and is Director of the Epilepsy Department at the Francisco Vitoria University of Madrid.
He was a founding member of the European Epilepsy Research Network and the European Association for Epilepsy Monitoring. He is also active in international research projects such as EpiCare and the European Epilepsy Brain Bank and has held relevant positions in international institutions such as the International Bureau for Epilepsy (IBE), the International League Against Epilepsy (ILAE), the European Federation of Neurological Societies (EFNS) and the World Federation of Neurology (WFN).
Dr. Gil-Nagel has directed numerous clinical trials and research studies in the field of epilepsy, especially in orphan epilepsies such as Dravet syndrome, Lennox-Gastaut syndrome and other epileptic and developmental encephalopathies. The Epilepsy Program he directs is an international benchmark in the development of pharmacological research. He has been the Principal Investigator of phase II and III clinical trials, including numerous clinical trials and non-pharmacological treatments (epilepsy surgery, electrical stimulation, ketogenic diet and gamma knife). His research is funded by European Union funds and the Public Innovation Agency of the Ministry of Science and Innovation of the Spanish Government. Their dedication to research and the development of new treatments allows them to accelerate the treatment of their patients with new treatments.
In addition to being a frequent speaker at national and international conferences, he has authored several books on epilepsy and electroencephalography and has numerous publications on epilepsy in journals such as Annals of Neurology, Brain, Epilepsy, European Journal of Neurology, Journal of Neurology, Nature Neurology, Neurology, and the New England Journal of Medicine, among others. He has authored 165 Scopus-indexed articles with 5,265 citations and an h-index of 35.
In 2021, his team received the Innovative Small and Medium Enterprise Award for the project on mesial temporal lobe epilepsy and encephalocele (Ministry of Science and Innovation, Spain), and in 2012, the Scientific Award from the Epilepsy Group of the Spanish Society of Neurology (SEN).
Dr. Hill-Nagel is a leading international figure in the field of epileptology, a recognized expert in the diagnosis and treatment of genetic epilepsy and the surgical approach to its correction. His distinguished professional career includes many years of experience in leading medical institutions in the United States and Europe, as well as active participation in international research and educational programs.
Dr. Hill-Nagel not only advances the science of neurology on a global level, but also successfully implements cutting-edge treatment methods, improving the lives of thousands of patients around the world.